TY - JOUR
T1 - Molecular mechanism regulating myosin and cardiac functions by ELC
AU - Lossie, Janine
AU - Köhncke, Clemens
AU - Mahmoodzadeh, Shokoufeh
AU - Steffen, Walter
AU - Canepari, Monica
AU - Maffei, Manuela
AU - Taube, Martin
AU - Larchevêque, Oriane
AU - Baumert, Philipp
AU - Haase, Hannelore
AU - Bottinelli, Roberto
AU - Regitz-Zagrosek, Vera
AU - Morano, Ingo
PY - 2014/7/18
Y1 - 2014/7/18
N2 - The essential myosin light chain (ELC) is involved in modulation of force generation of myosin motors and cardiac contraction, while its mechanism of action remains elusive. We hypothesized that ELC could modulate myosin stiffness which subsequently determines its force production and cardiac contraction. Therefore, we generated heterologous transgenic mouse (TgM) strains with cardiomyocyte-specific expression of ELC with human ventricular ELC (hVLC-1; TgMhVLC-1) or E56G-mutated hVLC-1 (hVLC-1E56G; TgM E56G). hVLC-1 or hVLC-1E56G expression in TgM was around 39% and 41%, respectively of total VLC-1. Laser trap and in vitro motility assays showed that stiffness and actin sliding velocity of myosin with hVLC-1 prepared from TgMhVLC-1 (1.67 pN/nm and 2.3 μm/s, respectively) were significantly higher than myosin with hVLC-1E56G prepared from TgME56G (1.25 pN/nm and 1.7 μm/s, respectively) or myosin with mouse VLC-1 (mVLC-1) prepared from C57/BL6 (1.41 pN/nm and 1.5 μm/s, respectively). Maximal left ventricular pressure development of isolated perfused hearts in vitro prepared from TgMhVLC-1 (80.0 mmHg) were significantly higher than hearts from TgME56G (66.2 mmHg) or C57/BL6 (59.3 ± 3.9 mmHg). These findings show that ELCs decreased myosin stiffness, in vitro motility, and thereby cardiac functions in the order hVLC-1 > hVLC-1E56G ≈ mVLC-1. They also suggest a molecular pathomechanism of hypertrophic cardiomyopathy caused by hVLC-1 mutations.
AB - The essential myosin light chain (ELC) is involved in modulation of force generation of myosin motors and cardiac contraction, while its mechanism of action remains elusive. We hypothesized that ELC could modulate myosin stiffness which subsequently determines its force production and cardiac contraction. Therefore, we generated heterologous transgenic mouse (TgM) strains with cardiomyocyte-specific expression of ELC with human ventricular ELC (hVLC-1; TgMhVLC-1) or E56G-mutated hVLC-1 (hVLC-1E56G; TgM E56G). hVLC-1 or hVLC-1E56G expression in TgM was around 39% and 41%, respectively of total VLC-1. Laser trap and in vitro motility assays showed that stiffness and actin sliding velocity of myosin with hVLC-1 prepared from TgMhVLC-1 (1.67 pN/nm and 2.3 μm/s, respectively) were significantly higher than myosin with hVLC-1E56G prepared from TgME56G (1.25 pN/nm and 1.7 μm/s, respectively) or myosin with mouse VLC-1 (mVLC-1) prepared from C57/BL6 (1.41 pN/nm and 1.5 μm/s, respectively). Maximal left ventricular pressure development of isolated perfused hearts in vitro prepared from TgMhVLC-1 (80.0 mmHg) were significantly higher than hearts from TgME56G (66.2 mmHg) or C57/BL6 (59.3 ± 3.9 mmHg). These findings show that ELCs decreased myosin stiffness, in vitro motility, and thereby cardiac functions in the order hVLC-1 > hVLC-1E56G ≈ mVLC-1. They also suggest a molecular pathomechanism of hypertrophic cardiomyopathy caused by hVLC-1 mutations.
KW - Essential myosin light chains
KW - In vitro motility
KW - Mutations
KW - Myosin
KW - Stiffness
UR - http://www.scopus.com/inward/record.url?scp=84904726536&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904726536&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2014.05.142
DO - 10.1016/j.bbrc.2014.05.142
M3 - Article
C2 - 24911555
AN - SCOPUS:84904726536
SN - 0006-291X
VL - 450
SP - 464
EP - 469
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 1
ER -